Anna Secher, a scientific director within Obesity and MASH (metabolic dysfunction-associated steatohepatitis) at Novo Nordisk, discussed what is known about how GLP-1R agonists gain access into the brain
Proteins Casein protein [129], whey proteins [130], peptones [131], and different amino acids such as l-glutamine [132], l-phenylalanine [133], L-tryptophan [134], and l-arginine induce GLP-1 secretion through activation of the calcium-sensing receptor (CaSR), the taste receptor TAS1R1/TAS1R3, G-protein-coupled receptor 6A (GPRC6A) [135], GPR142, peptide transporter-1 (PEPT1) [136], and amino acid (AA) transporter [137] (Fig
As the Ozempic boom takes shape, food and beverage companies have been among the first to roll out new products designed specifically to appeal to GLP-1 users
Theyre advertised as helping to reduce cravings, control appetite and support weight loss
The market has witnessed explosive growth, particularly with the emergence of dual- and tri-agonist formulations and extended applications in obesity, metabolic syndrome, and even addiction and Alzheimers disease